Nerea Zabaleta
Affiliations: | Harvard Medical School - Massachusetts Eye and Ear |
Area:
Gene therapy, adeno-associated virus, inherited disorders, liver, infectious diseases, vaccinesGoogle:
"Nerea Zabaleta"Parents
Sign in to add mentor| Gloria Gonzalez-Aseguinolaza | grad student | 2014-2019 | CIMA, Universidad de Navarra |
| Luk H. Vandenberghe | post-doc | 2019-2022 | Harvard Medical School - Massachusetts Eye and Ear |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Doshi J, Couto E, Staiti J, et al. (2024) E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells. Molecular Therapy. Methods & Clinical Development. 32: 101376 |
| Bhatt U, Herate C, Estelien R, et al. (2024) Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines. 12 |
| Torella L, Santana-Gonzalez N, Zabaleta N, et al. (2024) Gene editing in liver diseases. Febs Letters |
| Torella L, Klermund J, Bilbao-Arribas M, et al. (2024) Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. Embo Molecular Medicine. 16: 112-131 |
| Kumar P, Wang M, Kumru OS, et al. (2023) Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate. Molecular Therapy. Methods & Clinical Development. 30: 103-121 |
| Reichart D, Newby GA, Wakimoto H, et al. (2023) Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nature Medicine |
| Zabaleta N, Unzu C, Weber ND, et al. (2023) Gene therapy for liver diseases - progress and challenges. Nature Reviews. Gastroenterology & Hepatology |
| Zinn E, Unzu C, Schmit PF, et al. (2022) Ancestral library identifies conserved reprogrammable liver motif on AAV capsid. Cell Reports. Medicine. 100803 |
| Zabaleta N, Bhatt U, Hérate C, et al. (2022) Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Maciorowski D, Diop C, Bhatt U, et al. (2022) Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging. Viruses. 14 |